MeiraGTx Holdings plc (MGTX) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, MeiraGTx reported revenue of $81.4M, up 144.6% from $33.3M the year before. Net income was -$114.2M (a -140.3% net margin), or -$1.42 per diluted share. Operating margin was -130.2%. Operating activities generated -$46.4M of cash, leaving -$50.2M of free cash flow. At fiscal year end, MeiraGTx held $244.4M in total assets against $250.2M in total liabilities, including $65.9M of cash and equivalents.
Open the full interactive MeiraGTx financials → Quarterly statements, key ratios, valuation history and price charts.
MeiraGTx Key Stats
| Share Price | $9.94 |
|---|---|
| Market Cap | $932.4M |
| Revenue YoY Growth | +144.6% |
| 52-Week Range | $6.99 – $14.97 |
| Shares Outstanding | 91.4 million (basic, 2026 Q2) |
MeiraGTx Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $15.6M | $37.7M | $15.9M | $0 | $33.3M | $81.4M |
| Operating Income | -$62.6M | -$73.2M | -$116.4M | -$137.1M | -$164.2M | -$106.0M |
| Pre-Tax Income | -$58.0M | -$79.6M | -$129.6M | -$84.0M | -$147.8M | -$114.2M |
| Income Tax | $0 | $0 | -$1,000 | — | $0 | $0 |
| Net Income | -$58.0M | -$79.6M | -$129.6M | -$84.0M | -$147.8M | -$114.2M |
| Diluted EPS | -$1.54 | -$1.80 | -$2.87 | -$1.49 | -$2.12 | -$1.42 |
MeiraGTx Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $410,000 | $77.3M | $293,000 | $321.4M |
| Net Income | -$50.5M | $15.1M | -$46.3M | $160.7M |
| Diluted EPS | -$0.62 | $0.19 | -$0.57 | $1.71 |
MeiraGTx Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $209.5M | $137.7M | $115.5M | $129.6M | $103.7M | $65.9M |
| Current Assets | $272.6M | $183.2M | $154.3M | $159.6M | $123.5M | $91.8M |
| Total Assets | $363.7M | $320.2M | $318.2M | $326.7M | $269.8M | $244.4M |
| Current Liabilities | $54.1M | $68.1M | $82.1M | $67.1M | $60.8M | $122.6M |
| Total Long-Term Debt | — | $953,000 | $71.3M | $72.1M | $73.2M | $74.3M |
| Total Liabilities | $125.1M | $134.8M | $200.5M | $188.6M | $201.9M | $250.2M |
| Shareholders' Equity | $238.6M | $185.4M | $117.7M | $138.2M | $67.8M | -$5.8M |
MeiraGTx Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$64.0M | -$10.5M | -$73.1M | -$105.4M | -$104.5M | -$46.4M |
| Cash From Investing | -$37.0M | -$61.7M | -$45.0M | $34.0M | $23.5M | -$4.1M |
| Cash From Financing | $82.7M | $1.7M | $95.2M | $84.0M | $54.5M | $12.3M |
| Free Cash Flow | -$84.9M | -$56.9M | -$118.1M | -$125.6M | -$109.5M | -$50.2M |
Figures from MeiraGTx's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full MeiraGTx financials page for every line item.
MeiraGTx Company Profile
| Ticker | MGTX |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | New York, New York |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001735438 |
Frequently Asked Questions
What was MeiraGTx's revenue in fiscal 2025?
MeiraGTx (MGTX) reported revenue of $81.4M for fiscal 2025.
What is MeiraGTx's annual revenue history?
MeiraGTx's annual revenue by fiscal year: 2020: $15.6M; 2021: $37.7M; 2022: $15.9M; 2023: $0; 2024: $33.3M; 2025: $81.4M.
What was MeiraGTx's net income in fiscal 2025?
MeiraGTx reported net income of -$114.2M for fiscal 2025.
What was MeiraGTx's earnings per share (EPS) in fiscal 2025?
MeiraGTx's diluted EPS was -$1.42 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did MeiraGTx generate in fiscal 2025?
MeiraGTx generated -$50.2M of free cash flow in fiscal 2025.
What was MeiraGTx's revenue last quarter?
In its most recent reported quarter (2026 Q2), MeiraGTx reported revenue of $321.4M.
How much debt does MeiraGTx have?
MeiraGTx reported $74.3M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of MeiraGTx are outstanding?
MeiraGTx reported a weighted average of 91.4 million basic shares outstanding in 2026 Q2.
What is MeiraGTx's market cap?
Based on its latest closing price, MeiraGTx (MGTX) has a market capitalization of about $932.4M.
When does MeiraGTx's fiscal year end?
MeiraGTx's fiscal year end, as registered with the SEC, is December 31.
Where is MeiraGTx headquartered?
MeiraGTx lists its business address in New York, New York in its SEC filings.
MeiraGTx Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →